

GeneWatch



Joint media release

TEST
BIOTECH

Data from Monsanto do not meet basic scientific standards

Rising doubts about safety of genetically engineered plants

Bruxelles, 2.2.2012 In a letter to Commissioner Dalli, Testbiotech and GeneWatch UK give new evidence of EFSA's failure to perform risk assessment of genetically engineered plants. A detailed analysis of original documents as filed by Monsanto for their genetically engineered maize sold under brand of Genuity VT Triple PRO shows that crucial documents do not meet the standards of so called Good Laboratory Practice (GLP standards). As for example the company states in their investigation of the combinatorial toxicity of insecticides produced in the plants "there was no intention to conduct this study according to Good Laboratory Practice (GLP) Standards." Nevertheless the data were accepted by the European Food Safety Authority (EFSA) and the plants were accepted as being safe.

"EU Regulations require that *highest possible standards* are applied during risk assessment. But EFSA accepted data for risk assessment of a questionable product that would have been rejected for any scientific publication", says Helen Wallace from GeneWatch UK. "In conclusion, current practice is not in line with legal requirements."

The detailed analysis of the documents was conducted after the EU Commission rejected a formal complaint of GeneWatch (UK) and Testbiotech against the market authorisation of Monsanto's maize that is a combination of two genetically engineered plants (MON89034xMON88017, nickname SynthiToxStax). The Commission is of the opinion that risk assessment was conducted in accordance with EU regulations.

Now a tabled overview on the factual findings about SynthiToxStax, sent to the Commission today, shows the opposite. It is also shown that statements being made by EFSA's own experts give evidence that EFSA's current procedure of risk assessment is based on a flawed concept: The investigation of *substantial equivalence* is based on a comparison between the genetically engineered plants and their conventional counterparts. This comparison is regarded as the most crucial element in risk assessment as performed by EFSA. However as a quote from one of the leading members of EFSA's GMO panel, Joe Perry, shows this concept is flawed because EFSA is accepting a database set up by the International Life Science Institute (ILSI) for this purpose. In a public hearing in March 2011 Joe Perry stated that "*at the present time we can't trust the ILSI database*". But it was just this database from ILSI that was used by Monsanto to show safety of its SynthiToxStax. ILSI has strong ties with the biotech industry.

"While even statements from EFSA's own experts show that current risk assessment is not reliable, the Commission is still defending the opinions of the Food Safety Authority. So which interests does the Commission really serve?" asks Christoph Then from Testbiotech.

The genetically engineered maize is sold by Monsanto under brand Genuity VT Triple PRO Corn (event MON89034 x MON 88017). It produces a synthetic toxin, intended to kill insect pests. This

maize was approved for usage in food and feed by the EU Commission on 17th of June 2011. It produces a combination of three different insecticidal toxins, one of which is synthesised artificially. Further, the plants are made tolerant to the herbicide glyphosate (known as Roundup).

Contact:

Helen Wallace, + 44 7903 311584, helen.wallace@genewatch.org

Christoph Then, + 49 151 54638040, info@testbiotech.org

Joint letter to EU Commissioner Dalli: <http://www.testbiotech.de/node/616>

Tabled overview on risk assessment of SynthiToxStax: <http://www.testbiotech.de/node/615>

Original complaint from Testbiotech and GeneWatch UK, July 2011: <http://www.testbiotech.org/en/node/527>

Answer from EU Commissioner Dalli, November 2011: <http://www.testbiotech.de/node/617>

Tabled overview of comments on new draft EU Regulation on implementing risk assessment of genetically engineered plants: <http://www.testbiotech.org/en/node/613>